EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 3.0

Oral JAK and TYK2 Inhibitors for Lichen Planus: A Systematic Review of the Clinical Evidence and Safety

Shangshang Wang, Ying Zou

International Journal of General Medicine · 2026-11 · Volume 19 · 1-13

DOI: 10.2147/ijgm.s656848 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of General Medicine, 2026-11. Verfasst von Shangshang Wang und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lichen planus (LP) is a chronic T-cell-mediated inflammatory disorder with no approved targeted therapy, and JAK-STAT signaling driven by IFN-γ is central to its pathogenesis. This systematic review evaluated the efficacy and safety of oral JAK and TYK2 inhibitors across LP subtypes and critically appraised outcome definition heterogeneity. MEDLINE/PubMed and ClinicalTrials.gov were searched for original studies, and a descriptive synthesis was performed due to the predominance of case-level evidence. A total of 76 studies comprising more than 300 patients were included. Tofacitinib had the largest cumulative experience (23 reports, ≥ 180 patients), including a 74-patient lichen planopilaris (LPP) series and a placebo-controlled randomized trial. Baricitinib was supported by a Phase 2 trial (83.3% responders) and a randomized trial demonstrating superiority over hydroxychloroquine. Upadacitinib (21 reports, ≥ 36 patients) showed 77.8% remission in aggregate analyses. Abrocitinib (10 case reports) consistently produced complete or near-complete responses. Deucravacitinib (19 patients) showed efficacy in LPP and cutaneous disease, while ritlecitinib was reported in a single case. Adverse events were generally mild across all agents. Oral JAK and TYK2 inhibitors demonstrate promising efficacy in refractory LP; however, the lack of standardized outcome definitions severely limits cross-study comparability, and the development of an LP-specific core outcome set is urgently needed. Keywords: lichen planus, lichen planopilaris, Janus kinase inhibitors, TYK2 inhibitors

Zitieren

APA

Wang, S., & Zou, Y. (2026). Oral JAK and TYK2 Inhibitors for Lichen Planus: A Systematic Review of the Clinical Evidence and Safety. International Journal of General Medicine, Volume 19, 1-13. https://doi.org/10.2147/ijgm.s656848

Vancouver

Wang S, Zou Y. Oral JAK and TYK2 Inhibitors for Lichen Planus: A Systematic Review of the Clinical Evidence and Safety. International Journal of General Medicine. 2026;Volume 19:1-13. doi:10.2147/ijgm.s656848

BibTeX
@article{Wang2026,
  author = {Wang, Shangshang and Zou, Ying},
  title = {Oral JAK and TYK2 Inhibitors for Lichen Planus: A Systematic Review of the Clinical Evidence and Safety},
  journal = {International Journal of General Medicine},
  year = {2026},
  volume = {Volume 19},
  pages = {1--13},
  doi = {10.2147/ijgm.s656848}
}
Kostenlos starten →